Published in Endocrinology on October 11, 2007
Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One (2008) 2.96
Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest (2012) 2.10
Suppression of autophagy in osteocytes mimics skeletal aging. J Biol Chem (2013) 1.80
Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc Natl Acad Sci U S A (2012) 1.78
Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res (2008) 1.68
Control of RANKL gene expression. Bone (2009) 1.47
The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am (2010) 1.39
Osteocyte control of osteoclastogenesis. Bone (2012) 1.36
Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res (2012) 1.29
Fundamentals of vitamin D hormone-regulated gene expression. J Steroid Biochem Mol Biol (2013) 1.15
Regulation of gene expression by 1,25-dihydroxyvitamin D3 in bone cells: exploiting new approaches and defining new mechanisms. Bonekey Rep (2014) 1.10
An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3. Mol Endocrinol (2008) 1.08
Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res (2010) 1.06
Commitment to the osteoblast lineage is not required for RANKL gene expression. J Biol Chem (2009) 1.05
Molecular genetic studies of gene identification for osteoporosis: the 2009 update. Endocr Rev (2010) 1.00
Peripheral blood monocyte-expressed ANXA2 gene is involved in pathogenesis of osteoporosis in humans. Mol Cell Proteomics (2011) 0.99
Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region. J Biol Chem (2011) 0.93
Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. Bone (2014) 0.92
Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology (2014) 0.92
The mouse RANKL gene locus is defined by a broad pattern of histone H4 acetylation and regulated through distinct distal enhancers. J Cell Biochem (2011) 0.92
Genome-wide principles of gene regulation by the vitamin D receptor and its activating ligand. Mol Cell Endocrinol (2011) 0.92
Emerging regulatory paradigms for control of gene expression by 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol (2010) 0.90
Control of bone resorption in mice by Schnurri-3. Proc Natl Acad Sci U S A (2012) 0.90
Regulation of mouse Cyp24a1 expression via promoter-proximal and downstream-distal enhancers highlights new concepts of 1,25-dihydroxyvitamin D(3) action. Arch Biochem Biophys (2011) 0.87
Genome-scale techniques highlight the epigenome and redefine fundamental principles of gene regulation. J Bone Miner Res (2011) 0.87
The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice. Mol Endocrinol (2011) 0.86
Role of T cells in the modulation of PTH action: physiological and clinical significance. Endocrine (2013) 0.86
The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D3. Rheum Dis Clin North Am (2012) 0.85
Transcriptional regulation of the human TNFSF11 gene in T cells via a cell type-selective set of distal enhancers. J Cell Biochem (2015) 0.83
Osteoimmunology: oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease. Bonekey Rep (2014) 0.82
Genomic Determinants of Vitamin D-Regulated Gene Expression. Vitam Horm (2015) 0.80
RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease. Clin Dev Immunol (2013) 0.80
A DNA segment spanning the mouse Tnfsf11 transcription unit and its upstream regulatory domain rescues the pleiotropic biologic phenotype of the RANKL null mouse. J Bone Miner Res (2015) 0.80
Role of local vitamin D signaling and cellular calcium transport system in bone homeostasis. J Bone Miner Metab (2013) 0.79
Selective regulation of Mmp13 by 1,25(OH)2D3, PTH, and Osterix through distal enhancers. J Steroid Biochem Mol Biol (2015) 0.78
Deletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice. J Bone Miner Res (2016) 0.78
Pleiotropic Activities of Vitamin D Receptors - Adequate Activation for Multiple Health Outcomes. Clin Biochem Rev (2015) 0.76
The vitamin D receptor: contemporary genomic approaches reveal new basic and translational insights. J Clin Invest (2017) 0.75
Unique Distal Enhancers Linked to the Mouse Tnfsf11 Gene Direct Tissue-Specific and Inflammation-Induced Expression of RANKL. Endocrinology (2015) 0.75
SMURF2 regulates bone homeostasis by disrupting SMAD3 interaction with vitamin D receptor in osteoblasts. Nat Commun (2017) 0.75
SIKs control osteocyte responses to parathyroid hormone. Nat Commun (2016) 0.75
Deletion of a Distal RANKL Gene Enhancer Delays Progression of Atherosclerotic Plaque Calcification in Hypercholesterolemic Mice. J Cell Biochem (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest (1998) 5.03
Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology (2003) 2.84
Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology (1999) 2.47
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood (2007) 2.16
Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology (2004) 2.14
The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev (2005) 2.03
Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology (2001) 1.98
Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol (2006) 1.92
Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology (1999) 1.89
Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol (2006) 1.89
Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem (2002) 1.76
Attenuation of the self-renewal of transit-amplifying osteoblast progenitors in the murine bone marrow by 17 beta-estradiol. J Clin Invest (2001) 1.68
Enhancers located within two introns of the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3. Mol Endocrinol (2006) 1.66
Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res (1990) 1.55
NF-Y is essential for the recruitment of RNA polymerase II and inducible transcription of several CCAAT box-containing genes. Mol Cell Biol (2005) 1.52
IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab (2005) 1.41
Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone (1996) 1.37
Skeletal abnormalities in Pth-null mice are influenced by dietary calcium. Endocrinology (2003) 1.26
Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem (2003) 1.20
Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin Invest (2003) 1.18
Cbfa1 does not regulate RANKL gene activity in stromal/osteoblastic cells. Bone (2002) 1.15
Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun (2002) 1.11
In vivo evidence for the intermediary role of 3',5'-cyclic AMP in parathyroid hormone-induced stimulation of 1alpha,25-dihydroxyvitamin D3 synthesis in rats. Endocrinology (1977) 1.09
Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens (2003) 1.08
Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers. Mol Endocrinol (2006) 1.03
In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem (2003) 1.02
Modulation of mouse RANKL gene expression by Runx2 and PKA pathway. J Cell Biochem (2006) 0.98
Regulation of RANKL promoter activity is associated with histone remodeling in murine bone stromal cells. J Cell Biochem (2004) 0.98
Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol (2007) 0.98
Short-term changes in histomorphometric and biochemical turnover markers and bone mineral density in estrogen-and/or dietary calcium-deficient rats. Bone (1995) 0.96
Mechanisms involved in skeletal anabolic therapies. Ann N Y Acad Sci (2006) 0.94
Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans. J Clin Endocrinol Metab (1999) 0.90
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
Matrix-embedded cells control osteoclast formation. Nat Med (2011) 5.77
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76
Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med (2009) 4.39
Distinct molecular mechanism for initiating TRAF6 signalling. Nature (2002) 3.82
Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One (2008) 2.96
Arctic warming aloft is data set dependent. Nature (2008) 2.94
Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology (2003) 2.84
Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem (2007) 2.73
Nanoliter microfluidic hybrid method for simultaneous screening and optimization validated with crystallization of membrane proteins. Proc Natl Acad Sci U S A (2006) 2.66
Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology (2002) 2.50
Cultural tailoring for mammography and fruit and vegetable intake among low-income African-American women in urban public health centers. Prev Med (2004) 2.46
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology (2004) 2.44
Repeated growth and bubbling transfer of graphene with millimetre-size single-crystal grains using platinum. Nat Commun (2012) 2.44
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem (2003) 2.44
Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes (2003) 2.40
Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem (2007) 2.37
Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res (2006) 2.31
Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem (2001) 2.30
Bioactive glass in tissue engineering. Acta Biomater (2011) 2.23
Simulated versus observed patterns of warming over the extratropical Northern Hemisphere continents during the cold season. Proc Natl Acad Sci U S A (2012) 2.13
Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest (2012) 2.10
Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem (2012) 2.08
Surgical treatment of 31 complex traumatic posterior urethral strictures associated with urethrorectal fistulas. Eur Urol (2009) 2.05
Extracellular matrix made by bone marrow cells facilitates expansion of marrow-derived mesenchymal progenitor cells and prevents their differentiation into osteoblasts. J Bone Miner Res (2007) 1.99
Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest (2002) 1.99
Genetic and environmental effects on offspring alcoholism: new insights using an offspring-of-twins design. Arch Gen Psychiatry (2003) 1.92
Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol (2006) 1.92
1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J Bone Miner Res (2004) 1.90
Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol (2006) 1.89
Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest (2003) 1.84
Exploiting the reversibility of natural product glycosyltransferase-catalyzed reactions. Science (2006) 1.82
FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab (2010) 1.81
Suppression of autophagy in osteocytes mimics skeletal aging. J Biol Chem (2013) 1.80
The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol (2010) 1.79
Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem (2002) 1.76
Osteocyte apoptosis. Bone (2012) 1.73
PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res (2011) 1.72
Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab (2010) 1.72
Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell (2009) 1.72
The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. Mol Endocrinol (2006) 1.70
Uncoupling proton activation of vanilloid receptor TRPV1. J Neurosci (2007) 1.69
Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res (2008) 1.68
A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3. J Biol Chem (2010) 1.67
Isolation and analyses of genes preferentially expressed during early cotton fiber development by subtractive PCR and cDNA array. Nucleic Acids Res (2003) 1.67
Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res (2007) 1.66
Enhancers located within two introns of the vitamin D receptor gene mediate transcriptional autoregulation by 1,25-dihydroxyvitamin D3. Mol Endocrinol (2006) 1.66
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med (2012) 1.58
Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem (2004) 1.56
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res (2010) 1.54
Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates cortical porosity with age. J Bone Miner Res (2014) 1.52
Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem (2009) 1.50
Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone (2008) 1.48
Transpubic access using pedicle tubularized labial urethroplasty for the treatment of female urethral strictures associated with urethrovaginal fistulas secondary to pelvic fracture. Eur Urol (2008) 1.46
VDR/RXR and TCF4/β-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol Endocrinol (2011) 1.46
Significance of endothelial dysfunction in the pathogenesis of early and delayed radiation enteropathy. World J Gastroenterol (2007) 1.42
Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide. Biochemistry (2004) 1.42
IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab (2005) 1.41
Construction of introgression lines carrying wild rice (Oryza rufipogon Griff.) segments in cultivated rice (Oryza sativa L.) background and characterization of introgressed segments associated with yield-related traits. Theor Appl Genet (2005) 1.39
Draft genome sequence of the mulberry tree Morus notabilis. Nat Commun (2013) 1.38
Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens. J Biol Chem (2004) 1.38
Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest (2012) 1.36
Genome-wide analysis of the VDR/RXR cistrome in osteoblast cells provides new mechanistic insight into the actions of the vitamin D hormone. J Steroid Biochem Mol Biol (2010) 1.36
Multifunctional enhancers regulate mouse and human vitamin D receptor gene transcription. Mol Endocrinol (2009) 1.35
Use of cancer control referrals by 2-1-1 callers: a randomized trial. Am J Prev Med (2012) 1.35